<SEC-DOCUMENT>0001420506-25-000689.txt : 20250321
<SEC-HEADER>0001420506-25-000689.hdr.sgml : 20250321
<ACCEPTANCE-DATETIME>20250321191507
ACCESSION NUMBER:		0001420506-25-000689
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G/A
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20250321
DATE AS OF CHANGE:		20250321

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Evoke Pharma Inc
		CENTRAL INDEX KEY:			0001403708
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				208447886
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-87872
		FILM NUMBER:		25761940

	BUSINESS ADDRESS:	
		STREET 1:		420 STEVENS AVENUE
		STREET 2:		SUITE 230
		CITY:			SOLANA BEACH
		STATE:			CA
		ZIP:			92075
		BUSINESS PHONE:		858-345-1494

	MAIL ADDRESS:	
		STREET 1:		420 STEVENS AVENUE
		STREET 2:		SUITE 230
		CITY:			SOLANA BEACH
		STATE:			CA
		ZIP:			92075

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Bleichroeder LP
		CENTRAL INDEX KEY:			0001781002
		ORGANIZATION NAME:           	
		IRS NUMBER:				842006600
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A

	BUSINESS ADDRESS:	
		STREET 1:		1345 AVENUE OF THE AMERICAS
		STREET 2:		47TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10105
		BUSINESS PHONE:		917-769-2999

	MAIL ADDRESS:	
		STREET 1:		1345 AVENUE OF THE AMERICAS
		STREET 2:		47TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10105
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><!-- EDGARfilingagent.com Schedule 13D/G Online Workstation (https://schedule13d.com) --><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
<headerData>
	<submissionType>SCHEDULE 13G/A</submissionType>
	<previousAccessionNumber>0001781002-24-000024</previousAccessionNumber>
	<filerInfo>
		<filer>
			<filerCredentials>
				<cik>0001781002</cik>
				<ccc>XXXXXXXX</ccc>
			</filerCredentials>
		</filer>
		<liveTestFlag>LIVE</liveTestFlag>



	</filerInfo>
</headerData>
<!-- Start Form -->
  <formData>
<!-- Issuer Cover Page-->
    <coverPageHeader>
		<amendmentNo>2</amendmentNo>
      <securitiesClassTitle>Common Shares</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>03/19/2025</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001403708</issuerCik>
        <issuerName>Evoke Pharma, Inc.</issuerName>
        <issuerCusip>30049G203</issuerCusip>
        <issuerPrincipalExecutiveOfficeAddress>
          <com:street1>420 Stevens Avenue, Suite 370</com:street1>
          <com:city>Solana Beach</com:city>
          <com:stateOrCountry>CA</com:stateOrCountry>
          <com:zipCode>92075</com:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>
      <designateRulesPursuantThisScheduleFiled>
        <designateRulePursuantThisScheduleFiled>Rule 13d-1(b)</designateRulePursuantThisScheduleFiled>
      </designateRulesPursuantThisScheduleFiled>
    </coverPageHeader>
<!-- Reporting Persons Cover Page -->
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>Bleichroeder LP</reportingPersonName>
      <citizenshipOrOrganization>DE</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>849367</soleVotingPower>
        <sharedVotingPower>0</sharedVotingPower>
        <soleDispositivePower>849367</soleDispositivePower>
        <sharedDispositivePower>0</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>849367</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>9.99</classPercent>
      <typeOfReportingPerson>IA</typeOfReportingPerson>
    </coverPageHeaderReportingPersonDetails>
    <coverPageHeaderReportingPersonDetails>

      <reportingPersonName>Bleichroeder Holdings LLC</reportingPersonName>
      <citizenshipOrOrganization>DE</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>849367</soleVotingPower>
        <sharedVotingPower>0</sharedVotingPower>
        <soleDispositivePower>849367</soleDispositivePower>
        <sharedDispositivePower>0</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>849367</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>9.99</classPercent>
      <typeOfReportingPerson>HC</typeOfReportingPerson>
    </coverPageHeaderReportingPersonDetails>
    <coverPageHeaderReportingPersonDetails>

      <reportingPersonName>Andrew Gundlach</reportingPersonName>
      <citizenshipOrOrganization>X1</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>849367</soleVotingPower>
        <sharedVotingPower>0</sharedVotingPower>
        <soleDispositivePower>849367</soleDispositivePower>
        <sharedDispositivePower>0</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>849367</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>9.99</classPercent>
      <typeOfReportingPerson>HC</typeOfReportingPerson>
    </coverPageHeaderReportingPersonDetails>
<!-- Items -->
    <items>
      <item1>
        <issuerName>Evoke Pharma, Inc.</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>420 Stevens Avenue, Suite 370, Solana Beach, California 92075</issuerPrincipalExecutiveOfficeAddress>
      </item1>
      <item2>
        <filingPersonName>Bleichroeder Holdings LLC
Bleichroeder LP
Andrew Gundlach</filingPersonName>
        <principalBusinessOfficeOrResidenceAddress>1345 Avenue of the Americas, 47th Floor
New York, NY 10105</principalBusinessOfficeOrResidenceAddress>
        <citizenship>Bleichroeder Holdings LLC and Bleichroeder LP: Delaware, USA
Andrew Gundlach: United States</citizenship>
      </item2>
      <item3>
        <notApplicableFlag>N</notApplicableFlag>
      <typeOfPersonFiling>IA</typeOfPersonFiling>
      <typeOfPersonFiling>HC</typeOfPersonFiling>
      </item3>
      <item4>
        <amountBeneficiallyOwned>See cover page.</amountBeneficiallyOwned>
        <classPercent>See cover page.</classPercent>
        <numberOfSharesPersonHas>
          <solePowerOrDirectToVote>See cover page.</solePowerOrDirectToVote>
          <sharedPowerOrDirectToVote>See cover page.</sharedPowerOrDirectToVote>
          <solePowerOrDirectToDispose>See cover page.</solePowerOrDirectToDispose>
          <sharedPowerOrDirectToDispose>See cover page.</sharedPowerOrDirectToDispose>
        </numberOfSharesPersonHas>
      </item4>
      <item5>
        <notApplicableFlag>Y</notApplicableFlag>
        <classOwnership5PercentOrLess>N</classOwnership5PercentOrLess>
      </item5>
      <item6>
        <notApplicableFlag>N</notApplicableFlag>
        <ownershipMoreThan5PercentOnBehalfOfAnotherPerson>Bleichroeder LP ("Bleichroeder"), an investment adviser registered under Section 203 of the Investment Advisers Act of 1940, is deemed to be the beneficial owner of 849,367 shares, or 9.99%, of the common stock ("Common Stock") believed to be outstanding. The 849,367 shares include 825,000 shares of Common Stock and 24,367 shares of Common Stock issuable upon exercise of warrants. In accordance with the Warrant Agreements, exercise of the warrants are subject to a Beneficial Ownership Limitation (as defined in the agreements) of 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise. If there was no 9.99% limit on the exercise of warrants, Bleichroeder would be deemed to be the beneficial owner of 825,000 shares of Common Stock and 5,057,352 shares of Common Stock issuable upon exercise of the Warrants, representing 43.46% of the outstanding shares of Common Stock. The Denise and Michael Kellen Foundation, a charitable foundation for which Bleichroeder acts as investment adviser, holds the 825,000 shares, or 9.73% of Common Stock believed to be outstanding. The Denise and Michael Kellen Foundation also holds the 24,367 exercisable warrants of Evoke Pharma, Inc. The Denise and Michael Kellen Foundation holds the additional warrants above the 9.99% limit, which would make The Denise and Michael Kellen Foundation's total beneficial ownership 5,882,352 shares, or 43.46%, if there was no 9.99% limit. Clients of Bleichroeder have the right to receive and the ultimate power to direct the receipt of dividends from, or the proceeds of the sale of, such securities.</ownershipMoreThan5PercentOnBehalfOfAnotherPerson>
      </item6>
      <item7>
        <notApplicableFlag>N</notApplicableFlag>
        <subsidiaryIdentificationAndClassification>See Exhibit 99.2</subsidiaryIdentificationAndClassification>
      </item7>
      <item8>
        <notApplicableFlag>Y</notApplicableFlag>
      </item8>
      <item9>
        <notApplicableFlag>Y</notApplicableFlag>
      </item9>
      <item10>
        <notApplicableFlag>N</notApplicableFlag>
        <certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.</certifications>
      </item10>
    </items>
	<!-- Exhibit Information -->
	<exhibitInfo>Exhibit 99.1: Agreement of the Reporting Persons
Exhibit 99.2: Subsidiary Information
</exhibitInfo>
	<!-- Signature -->
    <signatureInformation>
      <reportingPersonName>Bleichroeder LP</reportingPersonName>
      <signatureDetails>
        <signature>Andrew Gundlach</signature>
        <title>Andrew Gundlach, Chairman and CEO</title>
        <date>03/21/2025</date>
      </signatureDetails>
    </signatureInformation>
    <signatureInformation>
      <reportingPersonName>Bleichroeder Holdings LLC</reportingPersonName>
      <signatureDetails>
        <signature>Andrew Gundlach</signature>
        <title>Andrew Gundlach, Chairman and CEO</title>
        <date>03/21/2025</date>
      </signatureDetails>
    </signatureInformation>
    <signatureInformation>
      <reportingPersonName>Andrew Gundlach</reportingPersonName>
      <signatureDetails>
        <signature>Andrew Gundlach</signature>
        <title>Andrew Gundlach, Individual</title>
        <date>03/21/2025</date>
      </signatureDetails>
    </signatureInformation>
	</formData>

</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>ex99-1.htm
<DESCRIPTION>AGREEMENT OF THE REPORTING PERSONS (500)
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 9pt Arial,sans-serif; margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 9pt Arial,sans-serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 9pt Arial,sans-serif; margin: 0"><B>AGREEMENT OF THE REPORTING PERSONS</B></P>

<P STYLE="font: 9pt Arial,sans-serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt Arial,sans-serif; margin: 0">The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is
filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf
of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each
shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning it
contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the other, except to
the extent that such person or entity knows or has reason to believe that such information is inaccurate. This agreement may be executed
in any number of counterparts and all of such counterparts taken together shall constitute one and the same instrument.&nbsp;</P>

<P STYLE="font: 9pt Arial,sans-serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 9pt Arial,sans-serif">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in; padding-left: 0">Date:</FONT></TD>
    <TD STYLE="padding-left: 0">March 21, 2025</FONT></TD></TR>
<TR>
<TD COLSPAN="2" STYLE="padding-left: 0">&nbsp;</TD></TR>
<TR><TD COLSPAN="2" STYLE="padding-left: 0">BLEICHROEDER LP</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0">Signature:</FONT></TD>
    <TD STYLE="padding-left: 0">/s/ Andrew Gundlach</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0">Name/Title:</FONT></TD>
    <TD STYLE="padding-left: 0">Andrew Gundlach, Chairman and CEO</FONT></TD></TR>
<TR>
<TD COLSPAN="2" STYLE="padding-left: 0">&nbsp;</TD></TR>
<TR><TD COLSPAN="2" STYLE="padding-left: 0">BLEICHROEDER HOLDINGS LLC</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0">Signature:</FONT></TD>
    <TD STYLE="padding-left: 0">/s/ Andrew Gundlach</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0">Name/Title:</FONT></TD>
    <TD STYLE="padding-left: 0">Andrew Gundlach, Chairman and CEO</TD></TR>
<TR>
<TD COLSPAN="2" STYLE="padding-left: 0">&nbsp;</TD></TR>
<TR><TD COLSPAN="2" STYLE="padding-left: 0">ANDREW GUNDLACH</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0">Signature:</FONT></TD>
    <TD STYLE="padding-left: 0">/s/ Andrew Gundlach</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0">Name/Title:</FONT></TD>
    <TD STYLE="padding-left: 0">Andrew Gundlach, Individual</TD></TR>
  </TABLE>



<P STYLE="font: 9pt Arial,sans-serif; margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>3
<FILENAME>ex99-2.htm
<DESCRIPTION>SUBSIDIARY INFORMATION (500)
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman , serif; color: rgb(0, 0, 0); text-align: right; text-indent: 0px; margin-top: 0; margin-bottom: 0">Exhibit
99.2</P>

<P STYLE="color: rgb(0, 0, 0); font: 10pt Times New Roman , serif; margin: 0; text-indent: 0px">&nbsp;</P>

<P STYLE="color: rgb(0, 0, 0); font: 10pt Times New Roman , serif; margin: 0; text-indent: 0px">&nbsp;</P>

<P STYLE="color: rgb(0, 0, 0); font: 10pt Times New Roman , serif; margin: 0; text-indent: 0px">The identity and the Item 3 classification
of the relevant subsidiary is: Bleichroeder LP, which is an Investment Adviser in accordance with Rule 13d-1(b)(1)(ii)(E).</P>

<P STYLE="font: 10pt Times New Roman , serif; color: rgb(0, 0, 0); margin: 0; text-indent: 0px">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
